bluebird bio (BLUE) Competitors $6.96 -0.07 (-1.00%) Closing price 02/4/2025 04:00 PM EasternExtended Trading$6.94 -0.02 (-0.23%) As of 02/4/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BLUE vs. FDMT, ITOS, LFVN, DSGN, ELDN, ACIU, MNPR, AQST, URGN, and YMABShould you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include 4D Molecular Therapeutics (FDMT), iTeos Therapeutics (ITOS), LifeVantage (LFVN), Design Therapeutics (DSGN), Eledon Pharmaceuticals (ELDN), AC Immune (ACIU), Monopar Therapeutics (MNPR), Aquestive Therapeutics (AQST), UroGen Pharma (URGN), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. bluebird bio vs. 4D Molecular Therapeutics iTeos Therapeutics LifeVantage Design Therapeutics Eledon Pharmaceuticals AC Immune Monopar Therapeutics Aquestive Therapeutics UroGen Pharma Y-mAbs Therapeutics bluebird bio (NASDAQ:BLUE) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Does the MarketBeat Community prefer BLUE or FDMT? bluebird bio received 990 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 70.99% of users gave bluebird bio an outperform vote while only 66.67% of users gave 4D Molecular Therapeutics an outperform vote. CompanyUnderperformOutperformbluebird bioOutperform Votes104070.99% Underperform Votes42529.01% 4D Molecular TherapeuticsOutperform Votes5066.67% Underperform Votes2533.33% Does the media prefer BLUE or FDMT? In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than bluebird bio. MarketBeat recorded 5 mentions for 4D Molecular Therapeutics and 2 mentions for bluebird bio. bluebird bio's average media sentiment score of 1.28 beat 4D Molecular Therapeutics' score of 0.20 indicating that bluebird bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bluebird bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BLUE or FDMT more profitable? 4D Molecular Therapeutics has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. 4D Molecular Therapeutics' return on equity of -28.00% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets bluebird bio-565.74% -322.46% -53.17% 4D Molecular Therapeutics N/A -28.00%-26.16% Which has better earnings & valuation, BLUE or FDMT? 4D Molecular Therapeutics has lower revenue, but higher earnings than bluebird bio. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobluebird bio$29.50M2.29-$211.91M-$37.40-0.194D Molecular Therapeutics$20.72M13.21-$100.84M-$2.85-2.08 Do insiders and institutionals hold more shares of BLUE or FDMT? 87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 1.4% of bluebird bio shares are owned by insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer BLUE or FDMT? bluebird bio presently has a consensus target price of $49.14, indicating a potential upside of 606.08%. 4D Molecular Therapeutics has a consensus target price of $38.56, indicating a potential upside of 551.28%. Given bluebird bio's higher possible upside, analysts clearly believe bluebird bio is more favorable than 4D Molecular Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bluebird bio 2 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.004D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 Which has more risk and volatility, BLUE or FDMT? bluebird bio has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Summary4D Molecular Therapeutics beats bluebird bio on 12 of the 18 factors compared between the two stocks. Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLUE vs. The Competition Export to ExcelMetricbluebird bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.65M$3.05B$5.66B$9.11BDividend YieldN/A1.81%5.28%4.00%P/E Ratio-0.1946.9088.3118.31Price / Sales2.29290.821,078.6376.66Price / CashN/A188.9637.4433.55Price / Book0.204.095.124.76Net Income-$211.91M-$41.02M$108.98M$223.10M7 Day Performance-10.31%2.01%0.67%-0.11%1 Month Performance-24.18%-4.73%-0.88%-1.99%1 Year Performance-63.60%-0.55%26.16%21.66% bluebird bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLUEbluebird bio2.3944 of 5 stars$6.96-1.0%$49.14+606.1%-63.6%$67.65M$29.50M-0.19520Short Interest ↓Positive NewsFDMT4D Molecular Therapeutics3.236 of 5 stars$5.91+5.6%$38.56+551.9%-66.2%$270.91M$20.72M-2.06120ITOSiTeos Therapeutics4.0208 of 5 stars$7.36-2.5%$22.25+202.5%-24.9%$269.15M$35M-2.3490LFVNLifeVantage4.5515 of 5 stars$21.51+1.7%$30.50+41.8%+324.7%$268.68M$200.16M67.06260Upcoming EarningsDSGNDesign Therapeutics1.7096 of 5 stars$4.73-2.5%$7.00+48.0%+103.4%$267.81MN/A-5.5640Short Interest ↑News CoverageGap DownELDNEledon Pharmaceuticals2.9492 of 5 stars$4.46-1.3%$12.50+180.3%+169.9%$267.58MN/A-2.2310Positive NewsACIUAC Immune2.5936 of 5 stars$2.71-1.5%$12.00+342.8%-11.4%$267.14M$16.48M-5.87140Positive NewsMNPRMonopar Therapeutics0.7715 of 5 stars$42.94-2.3%$43.00+0.2%+2,537.4%$264.88MN/A-22.0310AQSTAquestive Therapeutics1.628 of 5 stars$2.90-4.1%$11.00+280.0%+16.7%$263.97M$50.58M-6.43160Short Interest ↑Gap DownURGNUroGen Pharma3.8259 of 5 stars$11.19+1.7%$43.70+290.4%-31.4%$262.80M$82.71M-3.56200News CoverageYMABY-mAbs Therapeutics2.0122 of 5 stars$5.77-3.3%$20.89+261.8%-57.1%$259.46M$84.55M-10.73150News Coverage Related Companies and Tools Related Companies 4D Molecular Therapeutics Competitors iTeos Therapeutics Competitors LifeVantage Competitors Design Therapeutics Competitors Eledon Pharmaceuticals Competitors AC Immune Competitors Monopar Therapeutics Competitors Aquestive Therapeutics Competitors UroGen Pharma Competitors Y-mAbs Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLUE) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNew crypto boom will be greatest in historyUrgent Notice from Ian King, the Crypto Expert Who Made 18,325% in a Year: “Donald Trump’s second term is t...Banyan Hill Publishing | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
